873221-60-4

Basic information

• Product Name: 1-BOC-4-methoxy-4-methylpiperidine
• Synonyms: 1-BOC-4-methoxy-4-methylpiperidine
• CAS NO: 873221-60-4
• Molecular Formula: C12H23NO3
• Molecular Weight: 229.31592
• Mol File: 873221-60-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-methoxy-4-methylpiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-methoxy-4-methylpiperidine(873221-60-4)
• EPA Substance Registry System: 1-BOC-4-methoxy-4-methylpiperidine(873221-60-4)

Safety Data

• Hazardous Substances Data: 873221-60-4(Hazardous Substances Data)

Usage

Derivative of piperidine

Six-membered heterocyclic ring with one nitrogen atom This compound is based on the piperidine structure, which is a six-membered ring containing one nitrogen atom in the ring.

1-BOC

tert-Butoxycarbonyl (BOC) protecting group The "1-BOC" in the name indicates that a BOC protecting group is attached to the nitrogen atom of the piperidine ring, which serves to protect the nitrogen during chemical reactions.

Organic synthesis building block

Used in the preparation of various pharmaceuticals and biologically active compounds 1-BOC-4-methoxy-4-methylpiperidine is a valuable intermediate in organic synthesis, particularly for creating pharmaceuticals and other biologically active molecules.

Applications in research and development

Medicinal chemistry and pharmaceutical industry This compound is widely used in the fields of medicinal chemistry and the pharmaceutical industry for the creation of new drugs and the study of their properties and potential therapeutic uses.

Upstream product

• 406235-30-1 tert-butyl 4-hydroxy-4-methylpiperidine-1-carboxylate 
• 74-88-4 methyl iodide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1200131-27-6 1-(4-bromobenzyl)-4-methoxy-4-methylpiperidine 

Relevant articles and documents

PDE9 inhibitor and uses thereof

The invention belongs to the technical field of medicines, particularly relates to a PDE9 inhibitor compound shown as a formula (I) or pharmaceutically acceptable salt, isomer, a deuterated compound,metabolite and prodrug thereof, and further relates to pharmaceutical preparations, pharmaceutical compositions and application of the compounds. X1, X2, X3, X4, R1, R2, ring A, L and m are defined inthe specification. The compounds can be used for preparing medicines for treating or preventing related diseases mediated by PDE9.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

DIAZACARBAZOLES AND METHODS OF USE

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chkl) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.